Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Nov;23(7):872-902.
doi: 10.1111/pedi.13409. Epub 2022 Sep 25.

ISPAD Clinical Practice Consensus Guidelines 2022: Type 2 diabetes in children and adolescents

Amy S Shah  1 , Philip S Zeitler  2 , Jencia Wong  3 , Alexia S Pena  4 , Brandy Wicklow  5 , Silva Arslanian  6 , Nancy Chang  7 , Junfen Fu  8 , Preeti Dabadghao  9 , Orit Pinhas-Hamiel  10 , Tatsuhiko Urakami  11 , Maria E Craig  12   13
Affiliations
Review

ISPAD Clinical Practice Consensus Guidelines 2022: Type 2 diabetes in children and adolescents

Amy S Shah et al. Pediatr Diabetes. 2022 Nov.

Erratum in

Abstract

Since the 2018 ISPAD guidelines on this topic, follow-up of large cohorts from around the globe have continued informing the current incidence and prevalence of co-morbidities and complications in young adults with youth-onset type 2 diabetes (T2D). This chapter focuses on the risk factors, diagnosis and presentation of youth-onset T2D, the initial and subsequent management of youth-onset T2D, and management of co-morbidities and complications. We include key updates from the observational phase of the multi-center Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) clinical trial, the SEARCH for Diabetes in Youth (SEARCH) study and new data from the Restoring Insulin Secretion (RISE) study, a head-to-head comparison of youth onset vs adult-onset T2D. We also include an expanded section on risk factors associated with T2D, algorithms and tables for treatment, management, and assessment of co-morbidities and complications, and sections on recently approved pharmacologic therapies for the treatment of youth-onset T2D, social determinants of health, and settings of care given COVID-19 pandemic.

Keywords: obesity; pediatrics; type 2 diabetes; youth.

PubMed Disclaimer

References

REFERENCES

    1. Hannon TS, Arslanian SA. The changing face of diabetes in youth: lessons learned from studies of type 2 diabetes. Ann N Y Acad Sci. 2015;1353:113-137.
    1. Kim JY, Nasr A, Tfayli H, Bacha F, Michaliszyn SF, Arslanian S. Increased lipolysis, diminished adipose tissue insulin sensitivity, and impaired beta-cell function relative to adipose tissue insulin sensitivity in obese youth with impaired glucose tolerance. Diabetes. 2017;66(12):3085-3090.
    1. Kim JY, Bacha F, Tfayli H, Michaliszyn SF, Yousuf S, Arslanian S. Adipose tissue insulin resistance in youth on the spectrum from normal weight to obese and from normal glucose tolerance to impaired glucose tolerance to type 2 diabetes. Diabetes Care. 2019;42(2):265-272.
    1. Michaliszyn SF, Mari A, Lee S, et al. Beta-cell function, incretin effect, and incretin hormones in obese youth along the span of glucose tolerance from normal to prediabetes to type 2 diabetes. Diabetes. 2014;63(11):3846-3855.
    1. Bacha F, Gungor N, Lee S, Arslanian SA. Progressive deterioration of beta-cell function in obese youth with type 2 diabetes. Pediatr Diabetes. 2013;14(2):106-111.

LinkOut - more resources